The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study

M Mauer, R Stupp, M J B Taphoorn, C Coens, D Osoba, C Marosi, R Wong, O de Witte, J G Cairncross, F Efficace, R O Mirimanoff, P Forsyth, M J van den Bent, M Weller, A Bottomley, M Mauer, R Stupp, M J B Taphoorn, C Coens, D Osoba, C Marosi, R Wong, O de Witte, J G Cairncross, F Efficace, R O Mirimanoff, P Forsyth, M J van den Bent, M Weller, A Bottomley

Abstract

This is one of the few studies that have explored the value of baseline symptoms and health-related quality of life (HRQOL) in predicting survival in brain cancer patients. Baseline HRQOL scores (from the EORTC QLQ-C30 and the Brain Cancer Module (BN 20)) were examined in 490 newly diagnosed glioblastoma cancer patients for the relationship with overall survival by using Cox proportional hazards regression models. Refined techniques as the bootstrap re-sampling procedure and the computation of C-indexes and R(2)-coefficients were used to try and validate the model. Classical analysis controlled for major clinical prognostic factors selected cognitive functioning (P=0.0001), global health status (P=0.0055) and social functioning (P<0.0001) as statistically significant prognostic factors of survival. However, several issues question the validity of these findings. C-indexes and R(2)-coefficients, which are measures of the predictive ability of the models, did not exhibit major improvements when adding selected or all HRQOL scores to clinical factors. While classical techniques lead to positive results, more refined analyses suggest that baseline HRQOL scores add relatively little to clinical factors to predict survival. These results may have implications for future use of HRQOL as a prognostic factor in cancer patients.

References

    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365–376
    1. Blazeby JM, Brookes ST, Alderson D (2001) The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut 49: 227–230
    1. Bottomley A, Flechtner H, Efficace F, Vanvoorden V, Coens C, Therasse P, Velikova G, Blazeby J, Greimel E (2005) Health related quality of life outcomes in cancer clinical trials. Eur J Cancer 41: 1697–1709
    1. Bottomley A, Vanvoorden V, Flechtner H, Therasse P (2003) The challenge and achievements of implementation of quality of life research in cancer clinical trials. Eur J Cancer 39: 275–285
    1. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3): 570–579
    1. Cheng JD, Hitt J, Koczwara B, Schulman KA, Burnett CB, Gaskin DJ, Rowland JH, Meropol NJ (2000) Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol 18(2): 421–428
    1. Coates AS, Hurny C, Peterson HF, Bernhard J, Castiglione-Gertsch M, Gelber RD, Goldhirsch A (2000) Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. J Clin Oncol 18(22): 3768–3774
    1. Collett D (1994) Modelling Survival Data in Medical Research. Chapman & Hall: London
    1. Cox DR (1972) Regression models and life tables. J Royal Stat Soc 34: 187–220
    1. Cull A, Sprangers M, Bjordal K, Aaronson N (2002) EORTC Quality of Life Group Translation Procedure. EORTC Publications: Brussels, ISBN: 2-930064-28-5
    1. de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA (2001) Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur J Cancer 37: 332–339
    1. Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK (2002) Health-related quality-of-life assessments and patient–physician communication: a randomized controlled trial. JAMA 288(23): 3027–3034
    1. Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, Coleman RE, Calvert HA, Gamucci T, Twelves C, Fargeot P, Bottomley A (2004a) Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40(7): 1021–1030
    1. Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, Smit HJ, Gaafar R, Biesma B, Manegold C, Coens C, Giaccone G, Van Meerbeeck J (2006) Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 17(11): 1698–1704
    1. Efficace F, Therasse P, Piccart MJ, Coens C, van Steen K, Welnicka-Jaskiewicz M, Cufer T, Dyczka J, Lichinitser M, Shepherd L, de Haes H, Sprangers MA, Bottomley A (2004b) Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. J Clin Oncol 22(16): 3381–3388
    1. Fang FM, Tsai WL, Chiu HC, Kuo WR, Hsiung CY (2004) Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 58: 1394–1404
    1. Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 Scoring Manual. EORTC Publications: Brussels, ISBN: 2-930064-22-6
    1. Gorlia T, van den Bent MJ, Hegi M. Nomograms for predicting survival of patients with newly diagnosed glioblastoma multiforme: a prognostic factor analysis of EORTC/NCIC trial 26981-22981/CE. Clin Oncol (in press)
    1. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10): 997–1003
    1. Herndon JE, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J (1999) Is quality of life predictive of the survival of patients with advanced non-small cell lung carcinoma? Cancer 5 85(2): 333–340
    1. Klein M, Postma TJ, Taphoorn MJ, Aaronson NK, Vandertop WP, Muller M, van der Ploeg HM, Heimans JJ (2003) The prognostic value of cognitive functioning in the survival of patients with high-grade glioma. Neurology 61(12): 1796–1798
    1. Kramer JA, Curran D, Piccart M, de Haes JC, Bruning P, Klijn J, Van Hoorebeeck I, Paridaens R (2000) Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36: 1498–1506
    1. Langendijk H, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Wouters M (2000) The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol 55: 19–25
    1. Luoma ML, Hakamies-Blomqvist L, Sjöström J, Pluzanska A, Ottoson S, Mouridsen H, Bengtsson NO, Bergh J, Malmstrom P, Valvere V, Tennvall L, Blomqvist C (2003) Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. Eur J Cancer 39(10): 1370–1376
    1. Meyers CA, Hess KR, Yung WK, Levin VA (2000) Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18(3): 646–650
    1. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24(16): 2563–2569
    1. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR (2001) Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 31(2–3): 233–240
    1. Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E (1996) The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5(1): 139–150
    1. Sauerbrei W, Schumacher M (1992) A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 11: 2093–2109
    1. Sehlen S, Lenk M, Hollenhorst H, Schymura B, Aydemir U, Herschbach P, Duhmke E (2003) Quality of life (QoL) as predictive mediator variable for survival in patients with intracerebral neoplasma during radiotherapy. Onkologie 26(1): 38–43
    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10): 987–996
    1. Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer E, Forsyth P, Bottomley A (2005) Health-related quality of life in patients with glioblastoma: a randomized controlled trial. Lancet Oncol 6(12): 937–944
    1. Van Steen K, Curran D, Kramer J, Molenberghs G, Van Vreckem A, Bottomley A, Sylvester R (2002) Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection. Stat Med 21(24): 3865–3884
    1. Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, Selby PJ (2004) Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol 22(4): 714–724

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever